Precision Oncology

Precision oncology is the practice of choosing a cancer treatment by reading the molecular features of a patient's tumor rather than by its location in the body or its appearance under a microscope alone.

10 frameworks, from 1970 to today · Oncology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Precision oncology is the practice of choosing a cancer treatment by reading the molecular features of a patient's tumor rather than by its location in the body or its appearance under a microscope alone. Its central claim is that two breast cancers that look identical down the microscope may be driven by different broken genes, respond to different drugs, and behave as different diseases1. What is at stake is the oldest problem in cancer medicine: most conventional chemotherapy is a blunt instrument that kills dividing cells wherever they are, and works well only in some tumors. Precision oncology tries to match the drug to the defect, so that treatment is both more effective and less toxic2. The field grew out of a convergence of cancer genetics, medicinal chemistry, pathology, and clinical trial design over roughly the last fifty years, and it has changed not only what drugs are given but how cancers are named, how trials are run, and what a diagnosis even is.

The genetic view of cancer takes shape

The intellectual foundation was laid in the decades after the Second World War, when researchers established that cancer is fundamentally a disease of mutated genes. The discovery of the Philadelphia chromosome in chronic myeloid leukemia in 1960, and later the identification of the BCR-ABL fusion it produces, showed that a single chromosomal accident could drive a cancer. In the 1970s and 1980s, the discovery of oncogenes—normal genes that, when mutated or overexpressed, push cells toward uncontrolled growth—and of tumor suppressor genes such as TP53, which normally restrain growth, gave the field a vocabulary. By the 1980s, the somatic mutation theory was well established: cancers arise from mutations acquired in the body's cells over a lifetime, not inherited in the germline (though inherited mutations can raise risk).

This mattered clinically because it suggested a target. If a cancer depends on one hyperactive gene product, a drug that blocks that product might stop the cancer while sparing normal tissue. The term for this dependency is oncogene addiction: a tumor cell that has built its growth machinery around one mutant protein often cannot survive without it, even though normal cells can. The concept was articulated and popularized in the early 2000s, but its proof came earlier.

Imatinib and the first targeted success

The decisive demonstration was imatinib (Gleevec), developed in the late 1990s by a team at Novartis and approved by the U.S. Food and Drug Administration in 2001 for chronic myeloid leukemia. Imatinib is a small molecule that inhibits the ABL kinase, the enzyme produced by the BCR-ABL fusion31. In patients whose leukemia carried the fusion, the drug produced dramatic and durable remissions—a result that had been almost unimaginable in a cancer previously managed with interferon and stem-cell transplant. The lesson was not just that a targeted drug could work, but that it worked because the tumor carried the target. Testing for the fusion became part of diagnosis.

The same logic soon reached solid tumors. In the early 2000s, the drug trastuzumab, an antibody against the HER2 receptor, was shown to benefit breast cancers that overexpress HER2—roughly a fifth of cases. The companion test that identified those tumors, an immunohistochemical or fluorescence in situ hybridization assay for HER2, became one of the first widely used companion diagnostics: a test required to determine whether a drug is appropriate. Later, lung cancers with activating mutations in the EGFR kinase were found to respond to gefitinib and erlotinib, and the anaplastic lymphoma kinase (ALK) fusion in a subset of lung cancers to crizotinib. Each case followed the same pattern: identify a molecular subset, develop a drug against it, and require a test to find the patients.

Molecular taxonomy and the pathologist's new tools

As targeted drugs multiplied, the old classification of cancer by organ of origin and microscopic appearance began to strain1. Two lung adenocarcinomas that looked the same might harbor EGFR, ALK, KRAS, or none of these, with very different treatment implications. The response was a molecular taxonomy: a classification layered onto histology that sorts tumors by their driver alterations4. This was not a rejection of the microscope but an addition to it5. Pathology departments added sequencing and immunohistochemistry panels, and the diagnosis of, say, lung cancer came to include a molecular report.

The technology that made this practical was next-generation sequencing, which by the 2010s could read many genes at once from a small tumor sample. Comprehensive genomic profiling—sequencing hundreds of cancer-relevant genes in a single assay—became commercially available and entered routine use for advanced cancers. It generated more information than any single oncologist could interpret, which gave rise to the molecular tumor board: a multidisciplinary meeting of oncologists, pathologists, geneticists, and bioinformaticians who review a patient's genomic report and recommend a treatment, often an off-label drug or a clinical trial. The tumor board is a distinctly modern institution, a place where the interpretation of genomic data is negotiated collectively6.

Resistance and the clonal view

Targeted therapy brought a new problem: resistance. Imatinib produced remissions, but many patients relapsed as leukemia cells acquired new mutations in the BCR-ABL kinase that prevented the drug from binding. The same pattern appeared in lung cancer, where EGFR-mutant tumors treated with gefitinib or erlotinib often developed a secondary T790M mutation. The explanation came from clonal evolution: a tumor is not a uniform mass but a population of genetically diverse cells, and a drug kills the sensitive majority while leaving resistant subclones to expand. This model, developed through the 2000s and 2010s, reframed cancer as an evolving ecosystem and made resistance a predictable feature of targeted treatment rather than an occasional failure. It drove the development of second- and third-generation inhibitors (osimertinib for T790M-mutant lung cancer, for example) and of combination strategies meant to suppress resistance before it emerges.

Liquid biopsy and the monitoring problem

Repeated tumor biopsies are invasive and often impossible when a tumor is inaccessible or has shrunk. The solution was to detect tumor DNA in the blood7. Circulating tumor DNA (ctDNA)—fragments of DNA released by dying tumor cells into the bloodstream—can be sequenced from a blood draw, a procedure called liquid biopsy. The approach matured through the 2010s: it can reveal a tumor's mutations when tissue is unavailable, track whether a treatment is working by measuring ctDNA levels, and detect the emergence of resistance mutations before a scan shows progression. It remains an area of active development, with questions about sensitivity in early-stage disease and about how to act on the results.

Immunotherapy meets genomics

A parallel strand came from cancer immunology8. Immune checkpoint inhibitors—drugs that release the brakes on the immune system—were shown in the 2010s to produce durable responses in some cancers. The puzzle was which patients would respond8. One answer was genomic: tumors with many mutations, measured as tumor mutational burden, tend to produce more abnormal proteins that the immune system can recognize, and some such tumors respond better9. Another was the presence of mismatch-repair deficiency, a genetic state that generates thousands of mutations and, in 2017, led to the first approval of a drug (pembrolizumab) for any solid tumor with that biomarker regardless of where it arose. This was a landmark for genotype-directed immunotherapy: treatment chosen by a genomic feature rather than by cancer type.

Tumor-agnostic drug development

That 2017 approval crystallized a broader shift: tumor-agnostic, histology-independent drug development. Traditionally, a drug was approved for a cancer type—breast, lung, colon. But if a mutation drives cancer regardless of tissue of origin, a drug against it might work across types. The mismatch-repair approval was followed by others, including approvals for NTRK fusion-positive tumors and for BRAF V600E-mutant tumors across multiple histologies. The approach is not universal—the same mutation can behave differently in different tissues—but it established that a molecular feature can be a valid indication in its own right, and it forced regulators and trial designers to rethink what a "disease" is.

Where the field stands

Precision oncology today is built on these layers: molecular taxonomy and comprehensive genomic profiling as the diagnostic backbone; companion diagnostics to gate access to targeted drugs; molecular tumor boards to interpret the data; ctDNA monitoring to track response and resistance; and genotype-directed immunotherapy and tumor-agnostic approvals as the newest frontier. The field has real successes—imatinib in CML, EGFR and ALK inhibitors in lung cancer, HER2-directed therapy in breast cancer—and real limits. Most advanced cancers still lack a targetable driver, many targeted responses are temporary, and the cost and complexity of genomic testing raise questions of access. The open questions are biological and practical at once: how to predict which alterations are truly drivers, how to combine drugs to outpace clonal evolution, how to make liquid biopsy reliable enough for early detection, and how to extend the logic of precision to the immune system and to the tumor's surrounding tissue. The field's history is the story of a single idea—that the molecular details of a cancer should determine its treatment—being pursued through successive technologies, each solving the problem the last one exposed.

References

  1. Personalized medicine (Cancer genomics), Wikipedia
  2. Targeted therapy, Wikipedia
  3. Imatinib, Wikipedia
  4. Ash Alizadeh, Wikipedia
  5. Molecular pathology, Wikipedia
  6. Molecular tumor board, Wikipedia
  7. Circulating tumor DNA, Wikipedia
  8. Cancer immunotherapy (introduction, Immune checkpoint blockade), Wikipedia
  9. Tumor mutational burden, Wikipedia

The frameworks of Precision Oncology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1970-Present

    Somatic Mutation Theory of Cancer

    What causes a normal cell to become cancerous?

    Fly to its tower in Nousfarer

  2. 1998-Present

    Targeted Therapy and Companion Diagnostics

    How can a drug be matched to a tumor's molecular defect?

    Fly to its tower in Nousfarer

  3. 2000-Present

    Oncogene Addiction

    Why does a tumor depend on a single mutant gene?

    Fly to its tower in Nousfarer

  4. 2005-Present
  5. 2005-Present

    Somatic evolution in cancer

    How do tumors change and become resistant to treatment?

    Fly to its tower in Nousfarer

  6. 2010-Present

    Molecular Tumor Board

    How should genomic data be turned into a treatment decision?

    Fly to its tower in Nousfarer

  7. 2012-Present

    Liquid biopsy

    Can a tumor's genetics be read from a blood sample?

    Fly to its tower in Nousfarer

  8. 2013-Present

    Comprehensive Genomic Profiling

    How can many cancer genes be read at once?

    Fly to its tower in Nousfarer

  9. 2015-Present

    Genotype-Directed Immunotherapy

    Which patients will respond to immune-stimulating drugs?

    Fly to its tower in Nousfarer

  10. 2017-Present

    Tumor-Agnostic Drug Development

    Can a drug be approved for a mutation rather than a cancer type?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Somatic Mutation Theory of CancerTargeted Therapy and Companion Diagno…Oncogene AddictionMolecular Taxonomy of CancerSomatic evolution in cancerMolecular Tumor BoardLiquid biopsyComprehensive Genomic ProfilingGenotype-Directed ImmunotherapyTumor-Agnostic Drug Development

Beyond the field

Where Precision Oncology's ideas came from in other fields, and what they led to there: the strongest 12 of 44 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Precision Oncology is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Precision Oncology

Related fields

Fields its ideas are linked to

More in Oncology

See where Precision Oncology sits on the Map of Human Knowledge